We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

17 hedge funds and large institutions have $5.57M invested in Benitec Biopharma in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,147% more capital inflows, than outflows

Capital inflows: $2.76M | Capital outflows: $123K

41.91% more ownership

Funds ownership: 41.58% → 83.49% (+42%)

19% less funds holding

Funds holding: 21 → 17 (-4)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
17
Holders Change
-4
Holders Change %
-19.05%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Suvretta Capital Management
Suvretta Capital Management
New York
+$2.76M
2
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$709
3
Wells Fargo
Wells Fargo
California
+$4

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$47K
2
Walleye Capital
Walleye Capital
New York
-$45.3K
3
Virtu Financial
Virtu Financial
New York
-$15.4K
4
Two Sigma Investments
Two Sigma Investments
New York
-$5.61K
5
Cantor Fitzgerald
Cantor Fitzgerald
New York
-$5.26K

BNTC Hedge Fund Activity: Q2 2023 in Review

17 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q2 2023, worth a combined $5.57M — up 128% from $2.44M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of BNTC and 1 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Suvretta Capital Management, adding an estimated $2.76M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $47K sold.

  • 17 institutional investors held Benitec Biopharma (BNTC) as of Q2 2023, down from 21 in Q1 2023.
  • Funds reported $5.57M of Benitec Biopharma stock for Q2 2023, up 128% quarter-over-quarter.
  • 1 fund opened new Benitec Biopharma positions in Q2 2023 and 5 closed out, a net change of -4 holders.
  • The largest Benitec Biopharma buyer in Q2 2023 was Suvretta Capital Management, an estimated $2.76M added.
  • The largest Benitec Biopharma seller in Q2 2023 was Renaissance Technologies, an estimated $47K sold.

Based on aggregated 13F filings for Q2 2023.